A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial

Inclusion Criteria: * MS according to 2010 revised McDonald criteria (76); * Expanded disability status scale (EDSS) of 0-6.5 inclusive; * Disease duration of maximum 15 years and first signs or symptoms at least 6 months prior to enrolment in the study; * Active MS (relapsing and progressive): -1 relapse in the past year and/or * at least 1 enhancing lesion on brain MRI in the past year * new or enlarging T2 lesion(s) in comparison with a reference scan from maximum 1 year before * Neurologically stable with no evidence of relapse for at least 30 days prior to start of screening and throughout during the screening phase; * Positive T cell reactivity response to a mix of 7 myelin-derived peptides; * Able to sign informed consent; * Ability to comply with the protocol assessments; * Appropriate venous access. * Use of adequate contraceptive measures Exclusion Criteria: * Previous use of immunosuppressive or cytostatic treatment, including mitoxantrone, alemtuzumab or bone marrow transplantation or stem cell transplantation at any time prior to enrolment; * Treatment with fingolimod or natalizumab or dimethylfumarate or teriflunomide within the last 3 months prior to study enrolment; * Pregnancy or planning pregnancy in the next 12 months and breast feeding; * Drug or alcohol abuse; * Inability to undergo MRI assessments; * History of or actual signs of immunodeficiency or malignancies; * Concurrent clinically relevant cardiac, immunological, pulmonary, neurological, renal or other major disease; * Hepatitis B, C, HIV, Syphilis or tuberculosis * Splenectomy; * Dementia or severe psychiatric, cognitive or behavioral problems or other comorbidity that could interfere with the compliance to the protocol.